Introduction: Refusal of organ donation is influenced by a range of interconnected factors spanning donor characteristics, family dynamics, and intensive care unit (ICU) practices. This study explores the impact of donor or centre-related variables on organ donation refusal rates in Italian ICUs, among potential donors without expressed will. Methods: We conducted a retrospective analysis of 12,930 potential donors registered in the North Italian Transplant Program registry from 01/01/2010 to 31/03/2025. A linear mixed-effects model was applied to account for donor characteristics (age, timing and cause of death, geographic origin) and ICU-level variability with refusal of organ donation. Results: In multivariate analysis geographic origin was an independent predictor of refusal – particularly for donors from North Africa and Middle East (OR 9.59, IQR 6.25 – 14.72; p-value < 0.001), Asia (OR 7.76, IQR 5.69—10.57; p-value < 0.001), Africa (OR 6.81, IQR 4.44 – 10.45; p-value < 0.001) and eastern European (OR 2.65, IQR 2.17 – 3.23; p-value < 0.001). Also, time from event to death over 48 h was associated with higher refusal rate (OR 3.37, IQR 2.52 – 4.50, p-value < 0.001). In contrast, traumatic brain injury (OR 0.85, IQR 0.74 – 0.98; p-value 0.023) was protective. Finally, inter-ICU variability had a significant impact on refusal rates, as indicated by a Median Odds Ratio of 1.38. However, the multivariate model demonstrated weak predictive ability for organ donation refusal (AUC = 0.66). Conclusions: This study identifies several factors independently associated with organ donation refusal. However, the overall predictive ability based on available variables remains limited. To enable individualized interventions and effectively reduce refusal rates, more comprehensive and prospective data collection is warranted.
Background: Magnesium regulates neuronal excitability, NMDA receptor activity, and cerebrovascular tone. Dysmagnesemia is common in patients with acute brain injury (>65%), yet large randomized trials of magnesium neuroprotection have been neutral despite strong physiological rationale and consistent observational associations with outcomes. A key limitation may be diagnostic misclassification: the total serum magnesium poorly reflects the biologically active ionized fraction and may misclassify magnesium status in 20–85% of ICU patients during critical illness. Purpose: This narrative review synthesizes current evidence on magnesium physiology, measurement limitations, and clinical implications in neurocritical care. Overview: We discuss the mechanisms of magnesium depletion, outline the conceptual “two-hit” model (chronic deficiency plus acute ICU losses), and highlight the potential value of ionized magnesium for improved patient evaluation. Emerging syndrome-specific data suggest that magnesium disturbances are associated with prognostic signals. Improved phenotyping may help explain prior trial neutrality and support stratified approaches to magnesium monitoring and repletion. Future studies should evaluate magnesium-guided strategies and phenotype-driven trials to clarify the therapeutic role of magnesium in neurocritical care.
Background: Micronutrient abnormalities are frequent in critically ill patients and are associated with organ dysfunction, infection, and adverse outcomes. Yet randomized controlled trials of supplementation have largely failed to demonstrate a consistent mortality or organ-failure benefit. One possible contributor to this translational gap is a systematically under-characterized variable: gut failure. In critical illness, the intestinal barrier is disrupted, epithelial cell mass is depleted, transporter expression is impaired, the intestinal microvasculature exhibits severe dysfunction, and the microbiome undergoes profound dysbiosis. These alterations may collectively impair the absorptive, metabolic, and immunological functions upon which micronutrient homeostasis depends. Purpose: This structured narrative review (SANRA-guided; 202 records) first outlines the epidemiology of micronutrient deficiencies in the ICU and defines gut failure as a biological entity distinct from ileus. It then traces the mechanistic pathways by which a dysfunctional gut disrupts key micronutrients and links this gut–micronutrient axis to immune dysregulation. Overview: We critically appraise landmark ICU supplementation trials and examine whether the absence of gastrointestinal phenotyping, reliance on circulating surrogates of bioavailability, and neglect of microbiome–nutrient interactions may have contributed to heterogeneous or negative findings. Finally, we propose a hypothesis-generating, gut-integrated framework for future studies, comprising gut integrity stratification, microbiome phenotyping, phase-adapted timing and route selection, and microbiome restoration, to realign micronutrient interventions with the biology of the gut–microbiome–immune axis. Direct evidence that gut dysfunction modifies the response to supplementation is lacking.